Abstract:In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Design, Synthesis and Biological Evaluation of Sulfonylamidines As Potent C-Met Inhibitors by Enhancing Hydrophobic Interaction.

Discovering Potent Inhibitors Against C-Met Kinase: Molecular Design, Organic Synthesis and Bioassay

Design, synthesis and biological evaluation of novel <i>N</i>-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

Discovery, Optimization and Biological Evaluation for Novel C-Met Kinase Inhibitors

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

Design, Synthesis and Biological Evaluation of Novel α‐Acyloxycarboxamide‐Based Derivatives as c‐Met Inhibitors

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Structure-based Discovery of Novel 4-(2-fluorophenoxy)quinoline Derivatives As C-Met Inhibitors Using Isocyanide-Involved Multicomponent Reactions.

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

QSAR aided design of potent c‐Met inhibitors using molecular docking, molecular dynamics simulation and binding free energy calculation

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Design, Synthesis and Biological Evaluation of C-Met Kinase Inhibitors Bearing 2-Oxo-1,2-dihydroquinoline Scaffold

Discovery of Imidazopyridine Derivatives As Novel C-Met Kinase Inhibitors: Synthesis, SAR Study, and Biological Activity

3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxypyridine Based 3-Oxo-3,4-dihydroquinoxaline-2-carboxamide Derivatives As Potential C-Met Kinase Inhibitors.

Discovery of Novel Inhibitors for C-Met by Virtual Screening and Pharmacophore Analysis

Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2.

Molecular Modeling of Exquisitely Selective c-Met Inhibitors through 3D-QSAR and Molecular Dynamics Simulations.

Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors.

Identification and Synthesis of N′-(2-oxoindolin-3-ylidene)hydrazide Derivatives Against C-Met Kinase

Discovery of Potent 1H-Imidazo[4,5-b]pyridine-based C-Met Kinase Inhibitors Via Mechanism-Directed Structural Optimization.